BlackRock reports its AtriCure (ATRC) stake and identifies an iShares ETF with over 5% interest.
BlackRock, Inc. has filed an amended Schedule 13G/A, disclosing a 15.4% beneficial ownership stake in AtriCure, Inc. (ATRC), totaling 7,837,484 common shares. The filing indicates BlackRock holds sole voting power over 7,763,851 shares and sole dispositive power over all 7,837,484 shares. Additionally, the report identifies iShares Core S&P Small-Cap ETF as having an interest exceeding 5% in AtriCure's outstanding common stock.
Is AtriCure (ATRC) Fully Valued Following Its 70% Three Month Rally?
AtriCure (ATRC) has seen a significant 70% rally over the past three months, bringing its share price to US$55.14. Despite this surge, Simply Wall St's analysis suggests the stock is currently 1% overvalued, with a fair value estimated at $54.89, leaving little room for error. Future growth hinges on successful clinical trials that could expand its market, though risks from competing technologies and R&D spending remain.
AtriCure (ATRC) Stock Gets Fair Value Bump As Analysts Weigh Procedure Growth And Risks
AtriCure (ATRC) has seen its fair value price target increase from US$51.67 to US$54.89, driven by analysts considering new procedural factors like the STS Quality Metric and future BoX-NoAF POAF data, balanced against clinical and execution risks. BTIG raised its price target to US$55, citing the potential for increased use of the EnCompass Clamp, while UBS maintained a Buy rating with a revised US$50 target due to sustainable double-digit top-line growth. Freedom Capital downgraded ATRC to Hold, expecting positive BoX-NoAF POAF data but highlighting the reduced margin for error due to caveats in earlier supportive data.
AtriCure Cut to Hold From Buy by Freedom Capital Markets
Freedom Capital Markets downgraded AtriCure's stock rating from Buy to Hold. This change in rating indicates a revised outlook on the company's investment potential by the firm.
Freedom Capital downgrades AtriCure stock rating to hold, raises price target to $57
Freedom Capital has downgraded AtriCure Inc. (NASDAQ: ATRC) from Buy to Hold, while simultaneously raising its price target to $57, based on a 2027 estimated EBITDA multiple. This adjustment comes as AtriCure shares have doubled since June and are trading at significant premiums, despite a recent 8.2% pullback from its 52-week high. The firm anticipates positive data from the BoX-NoAF POAF study in early 2027, which could serve as a major sales and margin catalyst for the company.
Freedom Capital downgrades AtriCure stock rating to hold, raises price target to $57
Freedom Capital has downgraded AtriCure Inc. (NASDAQ:ATRC) to Hold from Buy, while simultaneously increasing its price target to $57, based on an estimated 25 times the company’s 2027 EBITDA. This adjustment comes after AtriCure's shares have nearly doubled since June, leading to the firm believing that mid-term growth acceleration is largely priced into the stock. Despite strong Q2 2026 earnings and revenue exceeding expectations, the stock is considered overvalued according to InvestingPro data, trading at a significant EV/EBITDA multiple of 78.
AtriCure, Inc. (ATRC) Stock forecasts
Argus has issued an Investment Rating of HOLD for AtriCure Inc (ATRC), lowering its target price to $61.00 from a previous undisclosed target. The report provides subratings across several categories, including a Medium Industry Subrating, Low Management and Growth Subratings, and a High Value Subrating, based on a report dated September 30, 2026.
Price to cash flow ratio of AtriCure, Inc. – HAN:A5I
This article provides financial information for AtriCure, Inc. (A5I) on the Hannover Stock Exchange, specifically highlighting its price to cash flow ratio. The content indicates that the market was closed at the time of publication and offers an overview of the company's financials, documents, news, and community discussions.
Return on equity % of AtriCure, Inc. – HAN:A5I
The article focuses on the "Return on equity %" financial metric for AtriCure, Inc. (A5I) listed on the Hannover Stock Exchange. It provides a snapshot of this specific financial data point without further analysis or context within the snippet provided. The content is primarily a data presentation page from TradingView.
Debt to assets ratio of AtriCure, Inc. – HAN:A5I
The article provides financial information for AtriCure, Inc. (A5I) on the Hannover Stock Exchange, specifically focusing on its debt to assets ratio. It appears to be a stub or a section within a larger financial data platform like TradingView, indicating that the detailed ratio value would be presented within the "Financials" section.
How Device Adoption Growth Will Impact AtriCure (ATRC) Stock
AtriCure (ATRC) has seen its shares close at US$60.77 due to accelerating adoption of its minimally invasive cardiac surgical devices and international expansion. While the company's operational focus remains on continued product adoption and international momentum, the stock trades above several fair value models. Analysts project AtriCure's revenue to reach US$807.4 million and earnings US$36.7 million by 2029, with some optimistic analysts forecasting even higher figures, but the current fair value suggests an 11% potential downside.
AtriCure (ATRC) Stock Looks Rich Against Its Sales Base
AtriCure (ATRC) has seen a strong 73.5% share price increase over the past year, leading to a valuation where its P/S ratio of 5.4x is higher than the Medical Equipment industry average. Simply Wall St's analysis suggests the stock might be rich against its sales base, indicating a premium is being paid for its revenues. The article presents both bull and bear cases, with analysts debating whether current catalysts justify the valuation or if expectations are already too high.
Atricure Insider Sold Shares Worth $271,140, According to a Recent SEC Filing
An insider at Atricure sold shares worth $271,140, as detailed in a recent SEC filing. This transaction indicates a notable insider sale within the company. Further details would typically be found in the comprehensive SEC report.
AtriCure CTO Salvatore Privitera sells $271,140 in stock
AtriCure's CTO, Salvatore Privitera, sold 4,519 shares of company stock for a total of $271,140 on September 23, 2026. This transaction was executed under a pre-arranged 10b5-1 trading plan. The sale occurred as AtriCure's stock is trading near its 52-week high, following strong Q2 2026 earnings and positive analyst adjustments.
Form 4 AtriCure Inc For: 24 September By Investing.com
This article from Investing.com is a brief notice about a Form 4 filing for AtriCure Inc. for September 24. It indicates the publication is related to stock market news, with a link to view comments and an associated stock ticker.
AtriCure CTO Salvatore Privitera sells $271,140 in stock By Investing.com
AtriCure CTO Salvatore Privitera sold 4,519 shares of company stock worth $271,140 on September 23, 2026, under a pre-arranged 10b5-1 trading plan. This sale occurred while AtriCure stock was near its 52-week high and after the company reported strong Q2 2026 earnings, though InvestingPro suggested the stock might be overvalued. Analysts have also recently adjusted their price targets for AtriCure upwards.
Atricure Insider Sold Shares Worth $271,140, According to a Recent SEC Filing
An insider at Atricure (NASDAQ: ATRC) has sold shares valued at $271,140, as disclosed in a recent SEC filing. This transaction follows other insider sales reported in recent months, alongside news of AtriCure, Inc. being added to various S&P indices and analyst rating adjustments. The article also provides a company profile, financial data, and analyst consensus for AtriCure, Inc.
AtriCure (ATRC) officer sells shares at $60 each under a trading plan.
AtriCure, Inc.'s Chief Technical Officer, Salvatore Privitera, sold 4,519 shares of common stock at $60 per share on September 23, 2026. This transaction was conducted under a pre-arranged 10b5-1 trading plan adopted on February 20, 2026. Following the sale, Privitera holds 142,745 shares directly.
Is AtriCure (ATRC) Overvalued Following Its Recent Share Price Surge?
AtriCure (ATRC) has seen a significant share price surge, up 66.13% over the past year, prompting questions about its valuation. Simply Wall St's analysis suggests the stock is currently 16% overvalued, with a fair value estimated at $51.67 compared to its recent close of around $59.96. The company's rapid revenue growth from innovative medical devices is highlighted, but potential risks such as competition in minimally invasive cardiac procedures are also noted.
After two September sales, AtriCure (ATRC) officer Salvatore Privitera proposes another worth $271,140.
AtriCure (ATRC) officer Salvatore Privitera has proposed selling 4,519 common shares valued at $271,140, with an approximate sale date of September 23, 2026. This follows two previous sales in September 2026: 3,657 shares for $201,135 on September 8 and 7,763 shares for $407,557.50 on September 2. The proposed sale, categorized as a Form 144 filing, involves shares acquired as Performance Shares on March 1, 2022.
AtriCure stock hits 52-week high at $59.91
AtriCure Inc. (ATRC) stock reached a 52-week high of $59.88, currently trading at $60.49, following a 63.01% increase over the past year. The company, valued at $2.99 billion, reported nearly 14% revenue growth and surpassed Q2 2026 earnings expectations. Analysts have raised price targets, reflecting confidence in AtriCure's market positioning and ongoing trials.
AtriCure, Inc. (ATRC) Stock Price, News, Quote & History
This page provides comprehensive financial information for AtriCure, Inc. (ATRC), including its current stock price, historical data, key statistics, and an overview of the company's business in medical instruments and supplies. It also features performance comparisons against the S&P 500, earnings trends, analyst insights, and valuation measures. The company specializes in devices for surgical cardiac tissue ablation and pain management.
AtriCure (ATRC) Stock Looks Pricey Against Its Sales Base
AtriCure (ATRC) stock has seen a significant 59.5% return over the past year, but its current P/S ratio of 5.2x is considerably higher than the Medical Equipment industry average of 2.9x, suggesting it may be overvalued relative to its sales base. While some analysts see potential for growth driven by new clinical adoptions, others express caution due to competitive risks from new market entrants. Investors should evaluate whether the company's commercial execution can justify this premium.
Stifel reiterates Buy rating on AtriCure stock, $65 target
Stifel maintained its Buy rating and $65 price target for AtriCure Inc. (NASDAQ: ATRC), noting the stock's 63% surge over the past year and its overvalued appearance according to InvestingPro. The firm highlighted AtriCure's exceeding revenue and profitability expectations, successful trial enrollments, and potential market expansion due to a new quality metric from the Society of Thoracic Surgeons. Analyst confidence is further supported by positive physician feedback on AtriCure's technology over competitors, and recent strong Q2 2026 earnings, despite a cautious outlook for the rest of the year.
Director Regina Groves Sells 5,313 Shares of AtriCure Inc (ATRC)
Regina Groves, a Director at AtriCure Inc (ATRC), sold 5,313 shares of the company on September 11, 2026, with shares trading at $54.22. This transaction is part of a broader pattern of insider selling at AtriCure, which contrasts with some institutional investors accumulating shares. GuruFocus's valuation indicates the stock is "Significantly Overvalued" at a price-to-GF-Value ratio of 1.36 and a high P/E ratio of 265.67.
Insider Selling: Regina E Groves Unloads $288K Of AtriCure Stock
Regina E. Groves, a Board Member at AtriCure (NASDAQ: ATRC), sold 5,313 shares of the company's stock for a total transaction value of $288,070, as disclosed in a recent SEC filing. AtriCure specializes in surgical treatments for atrial fibrillation and pain management, and the article provides a financial overview highlighting its revenue growth, gross margin, but also its below-average EPS and high valuation ratios. Insider transactions like this sale offer insights into a company's prospects, though a sale doesn't necessarily indicate a negative outlook.
AtriCure Director Regina E. Groves Sells 5,313 Shares at $54.22 Each (NASDAQ: ATRC)
AtriCure Director Regina E. Groves sold 5,313 shares of AtriCure (NASDAQ: ATRC) at $54.22 each on September 11, 2026. This sale represented approximately 13.3% of her previous holdings, leaving her with 34,546 shares. The transaction was disclosed through regulatory filings, providing insight into insider activity.
AtriCure director Regina Groves sells $288,070 of stock By Investing.com
AtriCure director Regina Groves sold 5,313 shares of company stock worth $288,070 on September 11, 2026, retaining 34,546 shares. This transaction follows strong Q2 2026 earnings for AtriCure, which surpassed Wall Street expectations, and positive analyst price target adjustments driven by trial results and new quality metrics.
AtriCure stock hits 52-week high at 55.83 USD
AtriCure Inc. (ATRC) stock reached a 52-week high of $55.83, reflecting strong investor confidence with a 59.75% increase over the past year and 82.74% over six months. Despite this, InvestingPro data suggests the stock may be overvalued. The company recently surpassed Q2 2026 earnings expectations, although the stock declined after hours due to a cautious outlook.
AtriCure Executive Stock Sale Analysis
AtriCure's CTO, Salvatore Privitera, sold 3,657 shares for approximately $201,000, while still retaining a significant equity position of 147,000 shares valued at $7.9 million. Despite this sale, AtriCure's stock has performed strongly, rising 55.5% over the past year, reflecting growth in the cardiac surgery and arrhythmia treatment sectors. Analysts, however, project a cautious outlook with a median one-year price target of $52, suggesting a potential 4.6% downside from the current price.
AtriCure CTO Salvatore Privitera sells $201,135 in shares By Investing.com
AtriCure CTO Salvatore Privitera sold 3,657 shares of common stock for $201,135 on September 8, 2026, as part of a 10b5-1 trading plan. The sale occurred while AtriCure stock is near its 52-week high and is considered overvalued by InvestingPro. Despite recent strong Q2 2026 earnings, the stock's future outlook is met with mixed analyst sentiment, with some increasing price targets due to new quality measures.
AtriCure CTO Salvatore Privitera sells $201,135 in shares
AtriCure CTO Salvatore Privitera sold 3,657 shares of common stock for $201,135 on September 8, 2026, pursuant to a 10b5-1 trading plan. This transaction occurred while AtriCure stock was trading near its 52-week high, having gained 51% in the past year. The company recently reported strong Q2 2026 earnings, exceeding analyst expectations, although its stock saw an after-hours decline due to a cautious outlook.
How Atricure Inc. (ATRC) Affects Rotational Strategy Timing
This article analyzes Atricure Inc. (ATRC) for its impact on rotational strategy timing, highlighting strong near-term and mid-term sentiment which could lead to long-term gains. It provides specific AI-generated trading strategies including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis for support and resistance levels. The report suggests compelling upside potential due to the absence of clear resistance above the current price.
AtriCure CTO Privitera Sells 7,763 Shares at $52.50 Each (NASDAQ: ATRC)
AtriCure Chief Technical Officer Privitera Salvatore sold 7,763 shares of the company's stock at $52.50 per share on September 2, 2026. Following this transaction, his total ownership in AtriCure stands at 150,921 shares. The sale was reported under SEC transaction code S.
AtriCure CTO Salvatore Privitera Sells 7,763 Shares via 10b5-1 Trading Plan
AtriCure, Inc.'s Chief Technical Officer, Salvatore Privitera, sold 7,763 shares of the company's common stock at $52.5 per share on September 2, 2026. This transaction was carried out under a pre-established 10b5-1 trading plan, which was adopted on February 20, 2026. After the sale, Privitera retained direct ownership of 150,921 shares of AtriCure common stock.
Atricure CTO Salvatore Privitera sells $407,557 in stock
Atricure CTO Salvatore Privitera sold 7,763 shares of AtriCure (NASDAQ:ATRC) common stock for $407,557 on September 2, 2026, at $52.50 per share, through a pre-arranged trading plan. This sale occurred while AtriCure shares were near their 52-week high, and following a strong Q2 2026 earnings report that beat analyst expectations, though the company issued a cautious outlook. Several analysts have raised their price targets for AtriCure based on its BoxX-NoAF trial and new quality measures.
Atricure stock hits 52-week high at $50.00
AtriCure Inc. stock reached a new 52-week high of $50.00, driven by a 58% return over the past six months and a 40.7% increase year-over-year. Despite the stock appearing overvalued according to InvestingPro, analysts from Needham, Piper Sandler, and BTIG have raised their price targets following strong Q2 2026 earnings and positive developments from the BoxX-NoAF trial and new quality measures.
AtriCure to Participate in the 2026 Wells Fargo Health Care Conference
AtriCure, Inc. announced its participation in the 2026 Wells Fargo Health Care Conference. The company's management will hold a fireside chat on September 8, 2026, at 10:15 a.m. EST, accessible via webcast. AtriCure specializes in surgical treatments for atrial fibrillation, LAA management, and post-operative pain management.
Is AtriCure (ATRC) Outperforming Other Medical Stocks This Year?
AtriCure (ATRC) has shown strong performance this year, with its stock gaining 21.8% compared to the Medical sector's average return of 5.9%. The company holds a Zacks Rank of #1 (Strong Buy) due to improving analyst sentiment and a positive earnings outlook. While AtriCure outperforms its Medical - Products industry, Aveanna Healthcare (AVAH) has delivered even higher returns within the broader Medical sector.
Piper Sandler raises AtriCure stock price target on quality measure
Piper Sandler has increased its price target for AtriCure Inc. (NASDAQ:ATRC) to $60 from $50, maintaining an Overweight rating, citing a new quality measure for pre-operative atrial fibrillation treatment. This measure is expected to boost AtriCure's open ablation business, potentially increasing its domestic market penetration from 31% to 45% by 2030 and contributing significantly to top-line growth. This positive outlook follows AtriCure's strong Q2 2026 earnings, which surpassed analyst expectations.
AtriCure chief legal officer sells $458,099 in stock
AtriCure's Chief Legal Officer, Karl S. Dahlquist, sold 9,370 shares of company stock for a total of $458,099. This transaction occurred on August 24, 2026, when the stock was near its 52-week high after a 54% surge. Despite the stock appearing overvalued by InvestingPro, the company recently surpassed Q2 2026 earnings expectations, and BTIG raised its price target for AtriCure.
Atrial Fibrillation Treatment Devices Market Trends and Forecast, 2035 | Includes Profiles of Abbott, AtriCure, Boston Scientific, Johnson & Johnson, and Medtronic
The global atrial fibrillation treatment devices market is projected to grow significantly from USD 9.6 billion in 2026 to USD 29.0 billion by 2035, driven by the increasing prevalence of atrial fibrillation, an aging population, and advancements in ablation and left atrial appendage closure technologies. Key growth opportunities include pulsed field ablation, advanced mapping catheters, and LAAC implants, with North America leading the market and Asia-Pacific expected to show the fastest regional growth. Prominent companies like Abbott, AtriCure, Boston Scientific, Johnson & Johnson, and Medtronic are expected to intensify competition through new product development, regulatory approvals, and strategic acquisitions.
AtriCure chief legal officer sells $458,099 in stock
Karl S. Dahlquist, Chief Legal Officer at AtriCure, Inc. (NASDAQ:ATRC), sold 9,370 shares for $458,099 on August 24, 2026, as the stock traded near its 52-week high. This sale follows AtriCure's strong Q2 2026 earnings, which surpassed Wall Street expectations, and a price target increase from BTIG. Despite positive financial results, investors remain concerned about the company's future outlook.
AtriCure (ATRC) legal chief sells shares outside 10b5-1 plan
AtriCure's Chief Legal Officer, Karl S. Dahlquist, sold 9,370 shares of common stock on August 24, 2026, at a weighted average price of $48.89 per share. This transaction was an open market sale and was not conducted under a Rule 10b5-1 trading plan. Following the sale, Dahlquist directly holds 87,319 AtriCure common shares.
AtriCure to Participate in the 2026 Wells Fargo Health Care Conference
AtriCure, Inc. (Nasdaq: ATRC) announced its participation in the 2026 Wells Fargo Health Care Conference. Management is scheduled for a fireside chat on Tuesday, September 8, 2026, at 10:15 a.m. Eastern Standard Time. Interested parties can access a live audio webcast through the "Investors" section of AtriCure's website.
AtriCure management will appear in a live investor chat Sept. 8
AtriCure, Inc. (Nasdaq: ATRC) announced its participation in the 2026 Wells Fargo Health Care Conference. Management is scheduled to host a fireside chat on September 8, 2026, at 10:15 a.m. Eastern Standard Time, which interested parties can access via a live audio webcast on the company's investor relations website. AtriCure specializes in surgical treatments for atrial fibrillation, left atrial appendage management, and post-operative pain management.
BTIG Maintains AtriCure(ATRC.US) With Buy Rating, Raises Target Price to $55
BTIG has reiterated its Buy rating for AtriCure (ATRC.US) and increased its target price for the stock to $55. This revision suggests a positive outlook from the firm regarding AtriCure's future performance.
BTIG raises AtriCure stock price target on new quality metric
BTIG raised its price target for AtriCure Inc. (NASDAQ:ATRC) to $55 from $45, maintaining a Buy rating, citing a new Society of Thoracic Surgeons quality metric expected to increase the use of AtriCure's Open Ablation products. This new metric could boost the company's U.S. Open Ablation revenue significantly in 2027 and 2028. Despite the stock trading near its 52-week high and appearing overvalued by some analyses, AtriCure recently surpassed Q2 2026 earnings expectations, although investor enthusiasm was tempered by the company's outlook.
AtriCure (ATRC) Soars 6.2%: Is Further Upside Left in the Stock?
AtriCure (ATRC) shares rose 6.2% following renewed investor optimism from its presentation at the Goldman Sachs Global Healthcare Conference, where management reiterated its goal of $1 billion in revenue by 2030 and highlighted market potential from clinical trials. Investors are also re-evaluating the value of these studies after AtriCure disclosed accelerated enrollment in its BoxX-NoAF trial. Despite the surge, the stock holds a Zacks Rank #3 (Hold) as consensus EPS estimates for the upcoming quarter have remained unchanged.
A Look at AtriCure Inc (ATRC) After 3.0% Gain -- GF Value $39.53 vs Price $48.98
AtriCure Inc (ATRC) shares rose 3.0% to $48.98, significantly above its GF Value™ of $39.53, indicating it is 23.9% overvalued. The company has a GF Score™ of 79/100, with strong financial strength and growth but lower profitability. While some gurus are increasing their stakes, insider selling of $3.0 million without buying raises a red flag for potential investors.
